Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia
50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation
CEL-SCI’s CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months
VIENNA, Va., May 18, 2026--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and clinical developments for Multikine (Leukocyte Interleukin, Injection)*.
https://finance.yahoo.com/sectors/healthcare/...00650.html